We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.47B
AUM Growth
+$23.6M
Cap. Flow
+$98.4M
Cap. Flow %
3.98%
Top 10 Hldgs %
53.52%
Holding
129
New
25
Increased
23
Reduced
34
Closed
26

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$125M
2
Z icon
Zillow
Z
+$35.8M
3
UBER icon
Uber
UBER
+$21.2M
4
CYCN icon
Cyclerion Therapeutics
CYCN
+$19.3M
5
HOOK
HOOKIPA Pharma
HOOK
+$12M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$48.8M
2
IFRX icon
InflaRx
IFRX
+$31.2M
3
ZGNX
Zogenix, Inc.
ZGNX
+$11M
4
WVE icon
Wave Life Sciences
WVE
+$9.71M
5
VICI icon
VICI Properties
VICI
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 63.4%
2 Consumer Discretionary 15.74%
3 Technology 4.81%
4 Communication Services 1.88%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
101
Viking Therapeutics
VKTX
$3.91B
$830K 0.03%
+100,000
New +$855K
REAL icon
102
The RealReal
REAL
$1.42B
$578K 0.02%
+20,000
New +$578K
DNTH icon
103
Dianthus Therapeutics
DNTH
$5.64B
$347K 0.01%
1,470
-11,030
-88% -$2.73M
AMRN
104
CALL
Amarin Corp
AMRN
$303M
– –
-25,000
Closed -$10.4M
APLS
105
DELISTED
Apellis Pharmaceuticals
APLS
– –
-300,000
Closed -$5.85M
BAC icon
106
CALL
Bank of America
BAC
$433B
– –
-2,000,000
Closed -$55.2M
CRNX icon
107
Crinetics Pharmaceuticals
CRNX
$8.87B
– –
-200,000
Closed -$4.55M
CTMX icon
108
CytomX Therapeutics
CTMX
$697M
– –
-200,000
Closed -$2.15M
DTIL icon
109
Precision BioSciences
DTIL
$180M
– –
-5,000
Closed -$2.69M
FOLD
110
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-500,000
Closed -$6.8M
GS icon
111
CALL
Goldman Sachs
GS
$293B
– –
-250,000
Closed -$48M
IFRX icon
112
InflaRx
IFRX
$253M
– –
-825,000
Closed -$31.2M
LRMR icon
113
Larimar Therapeutics
LRMR
$392M
– –
-58,333
Closed -$1.92M
QCOM icon
114
CALL
Qualcomm
QCOM
$169B
– –
-200,000
Closed -$11.4M
TIGR
115
UP Fintech Holding
TIGR
$856M
– –
-100,000
Closed -$1.29M
VICI icon
116
VICI Properties
VICI
$29.8B
– –
-400,000
Closed -$8.75M
VRDN icon
117
Viridian Therapeutics
VRDN
$2.13B
– –
-33,333
Closed -$1.4M
WVE icon
118
Wave Life Sciences
WVE
$1.13B
– –
-250,000
Closed -$9.71M
WHWK
119
Whitehawk Therapeutics
WHWK
$176M
– –
-103,893
Closed -$1.4M
CMRX
120
DELISTED
Chimerix, Inc.
CMRX
– –
-500,000
Closed -$1.05M
SWAV
121
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-150,000
Closed -$5.02M
CBAY
122
DELISTED
Cymabay Therapeutics
CBAY
– –
-600,000
Closed -$7.97M
ICPT
123
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-50,000
Closed -$5.59M
XLRN
124
CALL
DELISTED
Acceleron Pharma
XLRN
– –
-200,000
Closed -$9.31M
TRIL
125
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-150,000
Closed -$99K
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2019 Portfolio in Review

As of Q2 2019, Artal Group held 129 positions worth $2.47B, up 0.96% from $2.45B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Artal Group deployed $98.4M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was Avantor: 7,000,000 shares worth $134M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 64% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Moderna, an estimated $8.59M trimmed.

  • Artal Group's largest Q2 2019 buy was Avantor: 7,000,000 shares worth $134M.
  • Artal Group added most to Zillow in Q2 2019, an estimated $35.8M increase.
  • Artal Group's biggest Q2 2019 reduction was Moderna, cutting an estimated $8.59M.
  • Artal Group fully exited Array Biopharma Inc in Q2 2019, selling an estimated $48.8M.
  • Artal Group's ten largest holdings make up 54% of its $2.47B portfolio in Q2 2019.
  • Artal Group opened 25 new positions and closed 26 in Q2 2019.
  • Artal Group's portfolio value rose 0.96% quarter-over-quarter to $2.47B.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.